Table 1. Patient demographics and baseline characteristics for NEOREP Cohort (N = 326).
| Age, y, median (range) | 47 (25–76) |
| Age, n (%) | |
| ≤35 y | 38 (11) |
| 36–45 y | 100 (31) |
| 46–55 y | 107 (33) |
| >55 y | 81 (25) |
| Body weight, kg, median (range) | 63.5 (43–120) |
| Height, cm, median (range) | 164 (145–178) |
| BMI, n (%)* | |
| ≤25 kg/m2 | 197 (61) |
| 26–30 kg/m2 | 88 (27) |
| >30 kg/m2 | 40 (12) |
| Family history of breast cancer, n (%) | |
| No | 246 (76) |
| Yes | 79 (24) |
| Missing | 1 |
| Pregnancy <1 y prior to diagnosis, n (%) | |
| No | 315 (97) |
| Yes | 11 (3) |
| Menopausal status, n (%) | |
| Premenopausal | 199 (62) |
| Postmenopausal | 123 (38) |
| Missing | 4 |
| Tumor size, mm, median (range) | 40 (0–140) |
| T stage, n (%) | |
| T1 | 29 (9) |
| T2 | 212 (65) |
| T3 | 85 (26) |
| N stage, n (%) | |
| N0 | 142 (44) |
| N1 | 163 (50) |
| N2 | 17 (5) |
| N3 | 4 (1) |
| Elston-Ellis grade, n (%)* | |
| I | 4 (1) |
| II | 36 (11) |
| III | 282 (88) |
| Missing | 4 |
| Mitotic index, n, median (range) | 27 (1–138) |
| Mitotic index, n (%)* | |
| ≤10 | 45 (15) |
| 11–22 | 79 (26) |
| >22 | 180 (59) |
| Missing | 22 |
| Neoadjuvant chemotherapy type, n (%) | |
| Anthracycline | 49 (15) |
| Anthracycline/taxane | 252 (77) |
| Other | 25 (8) |
| Neoadjuvant chemotherapy cycles, n, median (range) | 8 (1–16) |
| Mammary surgery, n (%) | |
| Partial mastectomy | 259 (79) |
| Total mastectomy | 67 (21) |
| Mammaplasty, n (%) | |
| No | 265 (81) |
| Yes | 61 (19) |
| Axillary surgery, n (%) | |
| Sentinel node biopsy | 16 (5) |
| Axillary dissection | 293 (90) |
| Sentinel node biopsy + axillary dissection | 17 (5) |
| Histological tumor size, mm, median (range) | 10 (0–130) |
| Lymph nodes removed, n, median (range) | 12 (1–28) |
| Positive lymph nodes, n (%) | |
| 0 | 245 (75) |
| 1–3 | 49 (15) |
| 3–9 | 26 (8) |
| >9 | 6 (2) |
Note
* Data were missing or not evaluable for some patients and are not included in the denominator for percent calculations.